A poorly run study would have been stopped by the data monitoring committee by now. This could be done so the company could either feed off of any shred of positive data or stopped for futility for lack of evidence of any clinical benefit. AMRN would not have continued with this study and cost without a sense that they would succeed. Check out VVUS results if you want to see a poorly run CVOT.
News 
Market Data 
Discover 
